Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Weighted Average) (2016 - 2025)

ImmunityBio (IBRX) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $919.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 31.92% to $919.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $919.9 million through Dec 2025, up 31.92% year-over-year, with the annual reading at $919.9 million for FY2025, 31.92% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $919.9 million at ImmunityBio, down from $946.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $946.6 million in Q3 2025, with the low at $1.6 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $428.8 million, with a median of $444.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 99.56% in 2021, then surged 27677.41% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $389.2 million in 2021, then crashed by 97.66% to $9.1 million in 2022, then surged by 5495.0% to $508.6 million in 2023, then soared by 37.09% to $697.3 million in 2024, then surged by 31.92% to $919.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $919.9 million, $946.6 million, and $888.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.